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a b s t r a c t
Purpose: To our knowledge, no study has speciﬁcally assessed the time course of anxiety during
radiotherapy (RT). The objective of this study was to assess anxiety time courses in patients with non-
metastatic breast cancer.
Material and methods: This multicenter, descriptive longitudinal study included 213 consecutive patients
with breast cancer who completed visual analog scales (VASs) assessing state anxiety before and after the
RT simulation and the ﬁrst and last ﬁve RT sessions.
Results: Pre- and post-session anxiety mean levels were highest at the RT simulation (respectively,
2.9 ± 2.9 and 1.6 ± 2.5) and ﬁrst RT session (respectively, 3.4 ± 2.9 and 2.0 ± 2.4), then declined rapidly.
Clinically relevant mean differences (P1 cm on the VAS) between pre- and post-simulation/session
VAS scores were found only for the RT simulation (1.3 ± 2.7; p < 0.001) and ﬁrst RT session
(1.4 ± 2.4; p < 0.001). Five percent to 16% of patients presented clinically relevant anxiety (pre- and
post-simulation/session VAS scoresP 4 cm) throughout treatment.
Conclusions: To optimize care, RT team members should offer all patients appropriate information about
treatment at the simulation, check patients’ understanding, and identify patients with clinically relevant
anxiety requiring appropriate support throughout RT.
 2014 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 111 (2014) 276–280
Radiotherapy may generate many fears [1–3] that persist after
the start of treatment and despite information transmission [1].
Although some studies have shown that radiotherapy is generally
better accepted than what may be expected [3,4] and than other
treatments [5], other studies have also shown that it can be
associated with emotional distress [6–8] and especially anxiety
[3,5,7,9]. Ten to twenty percent of patients with cancer experience
anxiety before the start of radiotherapy [7] and 20–50% of patients
feel anxious during the ﬁrst days of treatment; these feelings tend
to decrease throughout the course of treatment, although results
have varied greatly across studies [7,10,11].
Anxiety related to a given radiotherapy session may be antici-
patory or the sign of clinically relevant anxiety [12]. Anticipatory
anxiety can be deﬁned as the appearance of anxious symptoms
and feelings in the days/hours before a feared event, and their
rapid decline after the event. It leads to autonomic arousal and
increases vigilance toward the environment [13], and may be
experienced by individuals with or without an anxiety disorder
[14]. A moderate level of anticipatory anxiety as an emotional sig-
nal can lead to defensive and coping reactions, and may enhance
adjustment [5,15,16]. This form of anxiety, however, can also lead
to uncontrolled ruminations and intrusive thoughts [17]. Anticipa-
tory anxiety is thus generally considered to be a normal reaction
that may sometimes lead to emotional distress [18] or be a sign
of clinically relevant anxiety.
Few studies have focused speciﬁcally on the time course of
anxiety throughout radiotherapy treatment. One study suggested
that anxiety ‘‘prior’’ to radiotherapy is associated with the lack of
information about treatment, side effects, and the procedure [2].
Another study suggested that anxiety at the ﬁrst radiotherapy ses-
sion is associated with psychological distress and some character-
istics of the radiotherapy environment (e.g., waiting room, linear
accelerator room), but not with patients’ coping strategies, cancer
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prognosis, or experience of other treatments [3]. To our knowledge,
no study has speciﬁcally assessed the time course of anxiety before
and after radiotherapy sessions.
The main objective of this study was to examine anxiety time
courses during radiotherapy in patients with non-metastatic breast
cancer. Anxiety was measured at the radiotherapy simulation and
at each radiotherapy session during the ﬁrst and last weeks of
radiotherapy treatment. Three time courses were considered. The
ﬁrst and second time courses considered anxiety levels just before
and after all radiotherapy simulation/sessions, respectively, and
the third time course considered the difference in anxiety levels
before and after simulation/sessions. Given the ‘‘unknown’’ factor
related to the initiation of radiotherapy, we hypothesized that pa-
tients would feel high levels of anxiety during the radiotherapy
simulation and ﬁrst week of radiotherapy, and lower levels of anx-
iety at the start of the last week of radiotherapy. Given the ‘‘un-
known’’ factor related to the termination of radiotherapy, we
hypothesized that patients’ anxiety levels would increase at the
last radiotherapy sessions. Given the ‘‘unknown’’ factor related to
radiotherapy administration, we hypothesized that the difference
in anxiety levels before and after radiotherapy simulation/sessions
would be clinically relevant during the ﬁrst week. As clinically rel-
evant anxiety requires appropriate support, we assessed the prev-
alence of this condition at different timepoints. We hypothesized
that a minority of patients would exhibit clinically relevant anxiety
and that this anxiety would remain stable throughout treatment.
Materials and methods
Subjects and setting
This study was part of an interuniversity research program con-
ducted in four radiotherapy units in Belgium. The program tested
the efﬁcacy of a communication skills training program on radio-
therapy team member communication and interdisciplinary work
[19]. Radiotherapy team members were invited to participate in
the study and asked to provide permission for their patients’ inclu-
sion. Local ethics committees approved the study. The results dis-
cussed in the present article were based only on patient data. All
consecutive patients who fulﬁlled the inclusion criteria were in-
vited to participate. Women aged P18 years with surgically trea-
ted primary breast cancer without metastasis, who were
receiving radiotherapy for the ﬁrst time, had no cognitive dysfunc-
tion, and provided written informed consent were included in the
study.
Study design and assessment
Independent investigators recruited patients for this multicen-
ter descriptive longitudinal study and assisted them in the comple-
tion of questionnaires. Patients’ anxiety levels were assessed at the
radiotherapy simulation and the ﬁrst and last ﬁve radiotherapy
sessions, respectively.
Questionnaires
Sociodemographic data. Patients provided demographic informa-
tion, including age, marital status, educational level, occupational
status, and cultural origin on a questionnaire.
Disease-related characteristics. Physicians provided data about
patients’ disease and treatment characteristics, including diagno-
ses (months since diagnosis, disease stage) and received or sched-
uled treatments (surgery, chemotherapy, radiotherapy,
hormonotherapy, biological therapy).
Measurement of anxiety level
Before and after the radiotherapy simulation, the ﬁrst ﬁve
radiotherapy sessions (ﬁrst week of radiotherapy), and the last ﬁve
radiotherapy sessions (last week of radiotherapy), patients were
asked to report their anxiety levels using a visual analog scale
(VAS). The VAS consisted of horizontal 10-cm line, with the ex-
treme left deﬁned as ‘‘not at all anxious’’ and the extreme right de-
ﬁned as ‘‘extremely anxious.’’ The VAS was used because such
scales have been shown to be appropriate and adequate for the
assessment of state anxiety [20–22] and is easy to complete.
The time course of anxiety level before radiotherapy simulation/
sessions was assessed by comparing patients’ state anxiety VAS
scores reported just before the radiotherapy simulation, ﬁrst ﬁve
sessions, and last ﬁve sessions of treatment.
The time course of anxiety level after radiotherapy simulation/ses-
sionswas assessed by comparing patients’ state anxiety VAS scores
reported just after the radiotherapy simulation, ﬁrst ﬁve sessions,
and last ﬁve sessions of treatment.
The time course of the difference in anxiety levels before and after
radiotherapy simulation/sessions was assessed by determining the
differences in state anxiety VAS scores reported just after and be-
fore the radiotherapy simulation, ﬁrst ﬁve sessions, and last ﬁve
sessions of treatment. As recommended by Mitchell [23,24], we
considered patients with both pre- and post-session VAS scor-
esP 4 cm to have clinically relevant anxiety and a differ-
enceP 1 cm between pre- and post-session VAS scores to be
clinically relevant.
Statistical analyses
State anxiety VAS scores obtained before and after the radio-
therapy simulation and sessions were compared using the Wilco-
xon matched-pairs test. One-way multivariate analysis of
variance (MANOVA) was used to compare all pre-session and
post-session state anxiety VAS scores, respectively. Bonferroni cor-
rection was then applied to these multiple comparisons. All tests
were two-tailed and the alpha level was set to 0.05. Analyses were




Of 340 consecutive patients approached, 47 (14%) did not meet
inclusion criteria and 47/293 (16%) eligible patients refused to par-
ticipate. During the course of the study, 10 (3%) patients decided to
stop the completion of questionnaires. Only patients who com-
pleted the state anxiety VAS at the radiotherapy simulation and
ﬁrst and ﬁfth radiotherapy sessions in the ﬁrst and last weeks of
radiotherapy were included. Twenty-three patients were not in-
cluded in the data analysis. Data from 213 (73%) patients were
analyzed.
Patients’ sociodemographic, disease, and treatment characteristics
All patients included in this study were middle aged (mean,
55 ± 11 years; range, 27.9–84.3 years); 75% (n = 159) were married
or cohabiting, 74% (n = 158) had at least high-school education, and
27% (n = 57) worked part or full time. The mean time since diagno-
sis was 4.4 [standard deviation (SD) = 3.2] months. The majority
(85%, n = 181) of patients had stage I or II disease. Most (78%,
n = 167) of them had undergone lumpectomy and about half
(53%, n = 112) had received chemotherapy. The radiotherapy treat-
ment comprised an average of 23 (SD = 3.2) sessions, and most
(71%, n = 151) patients attended booster sessions. Only 12%
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(n = 25) of patients had received biological therapy (Trastuzumab).
Hormonotherapy was scheduled for 70% (n = 150) of patients.
Time courses of anxiety levels
Table 1 and Fig. 1 display patients’ state anxiety VAS scores at
the radiotherapy simulation and ﬁrst and last ﬁve radiotherapy
sessions.
Anxiety level before radiotherapy simulation/sessions
Patients’ anxiety levels just before sessions were highest at the
radiotherapy simulation (mean, 2.9 ± 2.9) and ﬁrst radiotherapy
session (mean, 3.4 ± 2.9), then decreased rapidly and dramatically
at subsequent sessions in the ﬁrst week of radiotherapy. These
low levels of anxiety persisted during the last week of radiother-
apy. MANOVA revealed signiﬁcant changes (p < 0.001) in state
anxiety VAS scores before the simulation and ﬁrst and last ﬁve
radiotherapy sessions. After Bonferroni correction, only anxiety
levels at the simulation and ﬁrst session differed signiﬁcantly from
those at all other sessions (p < 0.001); moreover anxiety levels at
the simulation and ﬁrst session were not signiﬁcantly different
(p = 0.005).
Anxiety level after radiotherapy simulation/sessions
Patients’ anxiety levels just after sessions were low at the radio-
therapy simulation (mean, 1.6 ± 2.5) and slightly higher at the ﬁrst
session of treatment (mean, 2.0 ± 2.4), then decreased at subse-
quent sessions in the ﬁrst week of treatment and stabilized
through the end of treatment. MANOVA revealed signiﬁcant
changes (p < 0.001) in state anxiety VAS scores after the simulation
and ﬁrst and last ﬁve radiotherapy sessions. After Bonferroni cor-
rection, only anxiety level at the ﬁrst radiotherapy session differed
Table 1
Time course of anxiety during the simulation and the ﬁrst and last weeks of radiotherapy (RT): comparisons of anxiety levels just before and just after RT sessions and differences





Differences in anxiety levels
Before and after RT sessionsb
n Mean SD Mean SD Mean SD pc
Simulation (S) 213 2.9 2.9 1.6 2.5 1.3 2.7 <0.001
First week of radiotherapy
First RT session (F1) 213 3.4 2.9 2.0 2.4 1.4 2.4 <0.001
Second RT session (F2) 212 2.0 2.5 1.6 2.0 0.4 1.4 <0.001
Third RT session (F3) 208 1.5 1.9 1.3 1.8 0.2 0.9 <0.001
Fourth RT session (F4) 212 1.4 1.9 1.3 1.8 0.1 1.3 <0.001
Fifth RT session (F5) 213 1.4 1.9 1.2 1.7 0.2 1.0 <0.001
Last week of radiotherapy
First RT session (L1) 213 1.6 2.1 1.3 1.8 0.3 1.2 <0.001
Second RT session (L2) 200 1.6 2.1 1.3 1.9 0.3 1.2 <0.001
Third RT session (L3) 202 1.3 1.9 1.2 1.9 0.1 0.6 0.029
Fourth RT session (L4) 202 1.3 2.0 1.3 2.0 0.0 0.8 0.210
Fifth RT session (L5) 213 1.3 1.9 1.3 2.0 0.0 0.9 0.224
a Measured through state anxiety VAS scores (cm) before and after radiotherapy sessions.
b Measured through the difference between state anxiety VAS scores after and before sessions.
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°p < 0.001
Fig. 1. Time course of anxiety among patients during the simulation and the ﬁrst and last weeks of radiotherapy (RT). Comparisons of the levels of anxiety before and after
each RT session (measured on state anxiety VAS scores) through Wilcoxon matched-pairs tests; ⁄⁄⁄p < 0.001, ⁄p < 0.05; MANOVA time changes in state anxiety VAS scores
before and after the simulation and sessions; ¤S refers to RT simulation; ¤¤F1 to F5 refer to RT sessions in the ﬁrst week of RT; ¤¤¤L1 to L5 refer to RT sessions in the last week of
RT.
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signiﬁcantly from those at all other sessions (p < 0.001); moreover
anxiety level at the ﬁrst session was not signiﬁcantly different from
the simulation (p = 0.002).
Difference in anxiety before and after simulation/sessions
Signiﬁcant differences between pre- and post-session anxiety
levels were found at the simulation, all sessions in the ﬁrst week
of radiotherapy, and the ﬁrst three sessions in the last week of
radiotherapy (p values ranging from <0.001 to 0.029). Clinically rel-
evant (P1 cm) differences in pre- and post-session VAS scores
were found only at the simulation (mean, 1.3 ± 2.7) and the ﬁrst
session (mean, 1.4 ± 2.4). This difference decreased at the second
session (mean, 0.4 ± 1.4) and was almost completely absent at
the following sessions.
Evolution of clinically relevant anxiety rate over time
Fig. 2 shows the evolution over time of the rate of patients
reporting clinically relevant anxiety (pre- and post-session VAS
scoresP 4 cm). At the simulation, 13% of patients reported clini-
cally relevant anxiety. This rate was highest (16%) at the ﬁrst ses-
sion, then decreased (12%) at the second session and remained
stable (5–10%) at subsequent sessions in the ﬁrst and last weeks
of radiotherapy. It should be noted that some patients developed
clinically relevant anxiety during the course of treatment: 20
(9.4%) at the ﬁrst session, 7 (3.3%) at the second session, 4 (1.9%)
at the third session, 1 (0.5%) at the ﬁfth session in the ﬁrst week
of radiotherapy, and 6 (2.8%) at the ﬁrst session and 1 (0.5%) at
the second session in the last week of radiotherapy. No new case
of clinically relevant anxiety was observed at the fourth session
in the ﬁrst week of radiotherapy and at the last three sessions in
the last week of radiotherapy.
Discussion
The main objective of this study was to examine anxiety time
courses during radiotherapy for breast cancer. The results indicate
that anxiety levels decreased rapidly after the radiotherapy simu-
lation and ﬁrst radiotherapy session in most patients with non-
metastatic breast cancer. A small minority of patients experienced
clinically relevant anxiety, and their anxiety levels remained high
throughout treatment.
Patients’ anxiety levels were highest before and after the simu-
lation and ﬁrst treatment session. Pre-session anxiety levels were
generally higher than post-session levels in the ﬁrst and last weeks
of radiotherapy, but clinically relevant differences (differ-
enceP 1 cm between pre- and post-session VAS scores) were
found only for the simulation and ﬁrst session. Contrary to our
hypotheses and previous ﬁndings [1], we observed a rapid decline
in anxiety levels after the ﬁrst radiotherapy session. This may be
explained by the alleviation of many patients’ fears of the un-
known and of potential side effects (e.g., damage to internal or-
gans, burns, pain, fatigue) before starting radiotherapy and in the
ﬁrst days of treatment due to the absence of perceived side effects
during the ﬁrst session. The rapid decrease in anxiety levels thus
reﬂects patients’ habituation to treatment, which may have been
mediated by support provided by the radiotherapy team.
Contrary to our hypotheses, patients’ anxiety levels did not in-
crease during the last days of radiotherapy, which may be ex-
plained by patients’ relief at the end of lengthy radiotherapy
treatment. Anxiety levels might increase later, when patients face
concerns about their futures, such as those regarding the persis-
tence of physical symptoms, fear of recurrence, and return to work.
Anxiety levels measured during radiotherapy are lower than those
measured during other treatments, such as chemotherapy [5].
Thus, the results of the present study reﬂect a normal reaction
which seems to be mainly anticipatory as it decreases.
Although most patients’ anxiety levels were low and decreased
rapidly after the ﬁrst session, 5–16% of patients presented clinically
relevant anxiety (pre- and post-simulation/session VAS scoresP
4 cm) during treatment. This proportion corresponds to the preva-
lence of anxiety disorders in the general population (10–17%)
[25,26]. For these patients, anxiety was not only a normal anticipa-
tory reaction, but the sign of a clinically relevant anxiety. These
patients maintained disturbing levels of anxiety throughout radio-
therapy. In other words, these patients have a clinically relevant
anxiety separate from what is experienced during treatment. Their
levels of anxiety are thus not affected by habituation to treatment.
This study has several strengths. To our knowledge, it is the ﬁrst
investigation of the time courses of anxiety before and after
simulation/treatment sessions and throughout treatment. Second,
patients’ anxiety levels were measured repeatedly using the VAS,
a valid measure that is sensitive to change. Some limitations of
the study should also be mentioned. First, patients were assessed
13 16 12 8 7 5 8 10 9 10 9
87 84 88 92 93 95 92 90 91 90 91
Paents without clinically relevant anxiety
Paents with clinically relevant anxiety
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Fig. 2. Evolution over time of the rate of breast cancer patients with clinically relevant anxiety (pre- and post-simulation/session VAS scoresP 4 cm) and without clinical
anxiety (pre- and/or post-simulation/session < 4 cm). ¤S refers to radiotherapy (RT) simulation; ¤¤F1 to F5 refer to RT sessions in the ﬁrst week of RT; ¤¤¤L1 to L5 refer to RT
sessions in the last week of RT.
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only during the ﬁrst and last weeks of radiotherapy treatment.
Thus, our results do not reﬂect their psychological functioning dur-
ing the entire course of treatment or after its conclusion. Second,
our sample included only patients with non-metastatic breast can-
cer and the results may not be generalizable to other populations
of patients with cancer.
The results of this study allow us to make two recommenda-
tions to radiotherapy team members regarding the care of patients
with non-metastatic breast cancer. First, team members should be
aware that patients’ anxiety levels peak at the simulation and ﬁrst
treatment session due to fear of the unknown. Team members
should thus provide all patients with appropriate oral and written
(e.g., pamphlets, digital resources) information about radiotherapy
(e.g., procedures, side effects) at the simulation, and systemically
check patients’ comprehension and correct misunderstandings
when necessary. Second, team members should be aware that pa-
tients may present clinically relevant anxiety requiring appropriate
support throughout radiotherapy. Team members should thus
evaluate patients’ anxiety as early as possible using brief, effective
screening tools (e.g., VAS) that assess emotional states in general
and anxiety levels in particular. Such assessment is not time con-
suming and can readily identify patients who may require appro-
priate support and referral to mental health professionals for
personalized treatment. Ideally, team members should investigate
patients’ anxiety no later than the radiotherapy simulation, so that
they can implement support during radiotherapy as appropriate.
Team members should repeat this assessment of patients’ anxiety
each week of treatment to detect new cases of patients presenting
clinically relevant anxiety. Brief training of team members may
facilitate the implementation of these recommendations.
Although these results improve the understanding of the time
course of patients’ anxiety during radiotherapy and may be useful
for the organization of clinical care, further investigation of the
predictors of anxiety (sociodemographic, medical, psychological,
and social variables) is needed. Importantly, further research is also
needed to evaluate the efﬁcacy of support provided by team mem-
bers to patients throughout treatment, including the ways in which
they inform patients and early referrals to mental health profes-
sionals for appropriate support.
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